NCT01596413
Withdrawn
Phase 1
An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancuso® Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 6 to 12 Years)
ConditionsChemotherapy Induced Nausea and Vomiting
Overview
- Phase
- Phase 1
- Intervention
- Sancuso
- Conditions
- Chemotherapy Induced Nausea and Vomiting
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Primary Endpoint
- Plasma concentration
- Status
- Withdrawn
- Last Updated
- last year
Overview
Brief Summary
The purpose of this study is to determine the dosing strategy for adolescents aged 6 to 12 years.
Detailed Description
This is an open-label, multi-center, cross-over study in male and female pediatric cancer patients, aged 6 to 12 years of age who are receiving at least 2 cycles of emetogenic chemotherapy requiring 5-HT3 antagonist treatment of up to 5 days duration. The study is designed to evaluate the safety and PK of transdermal granisetron (Sancuso® patch) in a pediatric population (aged 6 to 12 years), using a population PK approach.
Investigators
Eligibility Criteria
Inclusion Criteria
- •6 to 12 years of age inclusive at screening.
- •Written patient or parental (or appropriate legal representative) IRB approved informed consent as appropriate.
- •Written patient assent (as appropriate).
- •Confirmed malignancy.
- •Scheduled to receive 2 or more cycles\* of emetogenic chemotherapy requiring 5-HT3 antagonist treatment.
- •Scheduled to receive one or more consecutive days of 5-HT3 antagonist treatment, per cycle, as CINV prophylaxis.
- •The cycles of chemotherapy must be consecutive (i.e. one followed by the other) but do not have to be the first and second cycle of a line of treatment.
Exclusion Criteria
- •Hypersensitivities, allergies or contraindications to study medications; intolerance of medical tape or sticking plaster.
- •Clinical or laboratory signs and symptoms of significant cerebral, cardiovascular, respiratory, renal, hepatobiliary, pancreatic or infectious disease, which in the Investigator's judgment may interfere with the study assessment or completion of the study.
- •Patients with a known history or predisposition to cardiac conduction interval abnormalities, including QT Syndrome, or known family history of long QT Syndrome or taking medications that are known to prolong the QT interval.
- •Patients scheduled to have routine surgery during the study duration.
- •Patients with a life expectancy of \< 6 months.
- •Scarring or significant skin disease on both upper arms.
- •Female patients who are pregnant or breast-feeding. All post menarche female patients must have a pregnancy test at screening.
- •Patients who are known or thought to be sexually active must use effective birth control.\*\*
- •Administration of other investigational drugs within 30 days preceding the screening visit, except for anticancer treatments.
- •Any conditions associated with non-compliance.
Arms & Interventions
Sancuso Arm
Transdermal Patch 34.3mg graniestron per patch, size 52cm2 Dose: 3.1mg/24 hrs
Intervention: Sancuso
IV Granisetron
Aqueous solution for IV administration 1 mg/mL ampoules Dose: 0.01mg/kg (maximum 1 mg)
Intervention: IV granisetron
Outcomes
Primary Outcomes
Plasma concentration
Time Frame: Up to 7 days
Analysis of the plasma concentration of Intravenous granisetron vs transdermal granisetron in pediatric patients receiving chemotherapy over two sequential cycles.
Secondary Outcomes
- Number of participants with adverse events, application site assessment and clinically significant changes in laboratory assessments over 2 cycles of chemotherapy(From screening until 15 days after the last dose of IV granisetron)
- Number of participants with change in ECG parameters(Through study completion, an average of 8 weeks)
- Number of participants with change in vital signs(Through study completion, an average of 8 weeks)
- Number of participants with change in physical assessment including height, weight, BMI and BSA(Through study completion, an average of 8 weeks)
Similar Trials
Completed
Phase 1
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 13 to 17 YearsChemotherapy Induced Nausea and VomitingNCT01596400Kyowa Kirin Pharmaceutical Development Ltd19
Withdrawn
Phase 1
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 YearsChemotherapy Induced Nausea and VomitingNCT01596426Kyowa Kirin Pharmaceutical Development Ltd
Withdrawn
Phase 1
Safety, Tolerability, and Pharmacokinetics of AMG 827 in Adolescents With AsthmaAsthmaNCT01395485Amgen
Completed
Phase 4
Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A PatientsHemophilia ANCT00914459Pfizer37
Recruiting
Phase 1
Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive TumorsNCT06441331ITM Solucin GmbH20